Transtornos neurológicos pós-COVID-19
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Descrever as principais manifestações neurológicas relacionadas a COVID-19. Revisão bibliográfica: Evidências cada vez mais sólidas demonstram o caráter multissistêmico da COVID-19, que é causada pelo SARS-CoV-2, destacando-se os mais diversos transtornos neurológicos que se manifestam na forma de síndromes (demencial, parkinsoniana, epiléptica, motora, amnésica, comportamentais, dentre outras). Além disso, estudos destacam as manifestações neurológicas com maior prevalência, tais como pode-se listar como mais prevalentes associadas ao Sistema Nervoso Central (SNC) as cefaleias, vertigens, crise epiléptica, alteração de consciência, ataxias e doença cerebrovascular aguda, ainda, doenças relacionadas ao sistema nervoso periférico (SNP) como distúrbios sensoriais, déficit no paladar, olfato, visão e além de quadros de dor. Considerações finais: Considerando as complicações neurológicas associadas à COVID-19, é fundamental reconhecer que o vírus SARS-CoV-2 não apenas afeta o sistema respiratório, mas também pode ter impactos significativos no sistema nervoso central e periférico. Estudos e relatos clínicos têm documentado uma variedade de manifestações neurológicas em pacientes com COVID-19, desde sintomas leves, como dor de cabeça e tontura, até complicações mais graves, como encefalopatia, acidente vascular cerebral (AVC), encefalite e síndrome de Guillain-Barré.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. ALLAHYARI F, et al. Covid-19 vaccines and neurological complications: a systematic review. Z Naturforsch C J Biosci, 2022; 78(1-2): 1-8.
3. AZZAM A, et al. The burden of persistent symptoms after COVID-19 (long COVID): a meta-analysis of controlled studies in children and adults. Virol J. 2024; 21(1): 16.
4. BRAGATTO MG, et al. Estudo das sequelas neuroanatômicas associadas à Síndrome Pós-COVID-19. Revista Eletrônica Acervo Saúde. REAS Vol. 2021; 13(12).
5. CENSI S, et al. Guillain-Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis. J Neurol, 2024; 271(3): 1063-1071.
6. CHEN WP, et al. Investigation of Neurological Complications after COVID-19 Vaccination: Report of the Clinical Scenarios and Review of the Literature. Critical Reviews in Microbiology, 2023.
7. COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices. Centers for Disease Control and Prevention, [S. l.], 2021. Disponível em: https ://www.cdc.gov/mmwr/volumes/70/wr/mm7032e4.htm#suggestedcitation. Acessado em: 11 de abril de 2024.
8. DESILLES JP, et al. Impact of COVID-19 on thrombus composition and response to thrombolysis: Insights from a monocentric cohort population of COVID-19 patients with acute ischemic stroke. J Thromb Haemost. 2022; 20(4): 919-928.
9. ELLUL MA, et al. Neurological associations of COVID-19. Lancet Neurol. 2020; 19(9): 767-783.
10. GOMES AS, et al. Associação entre o COVID-19 e manifestações neurológicas. Braz. J. of Develop. 2020; 6(11): 88950-88961.
11. GOMES LP, et al. Neurological and neuropsychiatric manifestations of post-COVID-19 condition in South America: a systematic review of the literature. Arq Neuropsiquiatr. 2024; 82(1): 1-8.
12. GONZÁLEZ-HERAZO MA, et al. Post-COVID 19 Neurological Syndrome: a fresh challenge in neurological management. Journal of Neurology and Neurosurgery. 2021; 55(4).
13. IGNÁCIO FG, et al. Prevalence and Associated Factors of SARS caused by Covid-19 in Adults and Aged People with Chronic Cardiovascular Disease: A Critical Analysis. Cardiol. 2020; 114(5): 805-16.
14. JARRAHI A, et al. Neurological consequences of COVID-19: what have we learned and where do we go from here? Journal of Neuroinflammation. PubMed. 2020.
15. KANDUC D, et al. Sobre os determinantes moleculares do ataque SARS- CoV-2. Journal of Clinical Immunology. 2020.
16. LUO W, et al. Ischemic stroke associated with COVID-19: a systematic review and meta-analysis. J Neurol. 2022; 269(4): 1731-1740.
17. MANZANO GS, et al. Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Leukoencephalitis Following COVID-19: Systematic Review and Meta-synthesis. Neurol Neuroimmunol Neuroinflamm. 2021; 8(6): 1080.
18. NEHME MD, et al. Symptoms after COVID-19 vaccination in patients with PASC. Journal of General Internal Medicine, 2022.
19. NING F, et al. Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: A systematic review and meta-analysis. Heliyon. 2023; 10(1): 23944.
20. ØSTERGAARD SD, et al. Thromboembolism and the Oxford– AstraZeneca COVID-19 vaccine: side-effect or coincidence? National Library of Medicine. 2021.
21. PATONE M, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nature Medicine. 2021; 2146(27): 2144–2153.
22. PIMENTEL V, et al. Guillain-Barré syndrome associated with COVID-19: A systematic review. Brain Behav Immun Health. 2023; 28: 100578.
23. PITLIYA AD, et al. A Systematic Review Unraveling the Intricate Neurological Spectrum of COVID-19: Manifestations, Complications, and Transformative Insights for Patient Care. Neurol India. 2024; 72(1): 11-19.
24. PLATTO SX, et al. COVID19: an announced pandemic. Cell Death & Disease. 2020; 11(9): 799.
25. PREMRAJ L, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. J Neurol Sci. 2022; 434: 120-162.
26. ROCHMAWATI E, et al. Persistent symptoms among post-COVID-19 survivors: A systematic review and meta-analysis. J Clin Nurs. 2024; 33(1): 29-39.
27. ROSENBLUM HG, et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices. Centers for Disease Control and Prevention. 2021.
28. RUS MA, et al. Acute Myocardial Infarction during the COVID-19 Pandemic: Long-Term Outcomes and Prognosis-A Systematic Review. Life (Basel). 2024; 14(2): 202.
29. SCHULTZ NH, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV- 19 Vaccination. The New England Journal of Medicine. 2021.
30. SHEN Y, et al. Association of seizures with COVID-19 infection in underage during the pandemic: A systematic review and meta-analysis. Epilepsy Res. 2023; 197: 107223.
31. SHI Y, et al. COVID-19 infection: the perspectives on immune responses. Version 2 Cell Death Differ. 2020; 27: 1451-1454.
32. STOIAN A, et al. The Occurrence of Acute Disseminated Encephalomyelitis in SARS-CoV-2 Infection/Vaccination: Our Experience and a Systematic Review of the Literature. Vaccines (Basel). 2023; 11(7): 1225.
33. VALENTE F, et al. Vacinação obrigatória é constitucional. ConJur. 2020; 12(9): 1529.
34. WHO. WORLD HEALTH ORGANIZATION. Coronavirus disease (COVID-19) outbreak. Geneva: World Health Organization, 2020.
35. YAO M, et al. Disentangling the common genetic architecture and causality of rheumatoid arthritis and systemic lupus erythematosus with COVID-19 outcomes: Genome-wide cross trait analysis and bidirectional Mendelian randomization study. J Med Virol. 2023; 95(2): 28570.
36. ZHANG JJ, et al. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clin Rev Allergy Immunol. 2023; 64(1): 90-107.